期刊
BIOACTIVE MATERIALS
卷 6, 期 3, 页码 697-711出版社
KEAI PUBLISHING LTD
DOI: 10.1016/j.bioactmat.2020.09.002
关键词
Non-hodgkin lymphoma; DCs targeting; Man-EG7/CH@CpG vaccine; Combinational therapy
资金
- National Natural Science Fund for Distinguished Young Scholar [NSFC31525009]
- National Natural Science Foundation of China [NSFC31930067, NSFC31771096, NSFC31871008, NSFC31500809]
- National Key Research and Development Program of China [2017YFC1103502]
- 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYGD18002]
The study developed a novel tumor vaccine named Man-EG7/CH@CpG using a biomaterial-based strategy, which showed enhanced anti-tumor effects in lymphoma prevention and treatment models. A combination therapy incorporating a chemotherapeutic drug (doxorubicin) into the vaccination process achieved a tumor inhibition rate of approximately 85%, surpassing the efficacy of mono-chemotherapy or mono-immunotherapy. This strategy may offer a new direction for tumor vaccine development and prioritization of immuno-chemotherapy for Non-Hodgkin lymphoma.
In recent years, Non-Hodgkin lymphoma (NHL) has been one of the most fast-growing malignant tumor diseases. NHL poses severe damages to physical health and a heavy burden to patients. Traditional therapies (chemotherapy or radiotherapy) bring some benefit to patients, but have severe adverse effects and do not prevent relapse. The relevance of emerging immunotherapy options (immune-checkpoint blockers or adoptive cellular methods) for NHL remains uncertain, and more intensive evaluations are needed. In this work, inspired by the idea of vaccination to promote an immune response to destroy tumors, we used a biomaterial-based strategy to improve a tumor cell-based vaccine and constructed a novel vaccine named Man-EG7/CH@CpG with antitumor properties. In this vaccine, natural tumor cells are used as a vector to load CpG-ODN, and following lethal irradiation, the formulations were decorated with mannose. The study of the characterization of the double-improved vaccine evidenced the enhanced ability of DCs targeting and improved immunocompetence, which displayed an antitumor function. In the lymphoma prevention model, the Man-EG7/CH@CpG vaccine restrained tumor formation with high efficiency. Furthermore, unlike the non-improved vaccine, the double-improved vaccine elicited an enhanced antitumor effect in the lymphoma treatment model. Next, to improve the moderate therapeutic effect of the mono-treatment method, we incorporated a chemotherapeutic drug (doxorubicin, DOX) into the process of vaccination and devised a combination regimen. Fortunately, a tumor inhibition rate of similar to 85% was achieved via the combination therapy, which could not be achieved by mono-chemotherapy or mono-immunotherapy. In summary, the strategy presented here may provide a novel direction in the establishment of a tumor vaccine and is the basis for a prioritization scheme of immuno-chemotherapy in enhancing the therapeutic effect on NHL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据